Other International projects

Other International projects

Molecular Diagnosis, Prognosis, and Therapeutic Targets in Mantle Cell Lymphoma

PI: CAMPO GUERRI, ELIAS
Funding: Mayo Clinic Arizona
Beneficiary organization: FRCB-IDIBAPS
Reference: NIH_PAR-16-457_01
Amount: 680,686.05 €
Duration: 19/09/2018 to 31/08/2023

II Synergy Workshop on Translational and Clinical Oncology applied to Environmental & Occupational Cancer: Focus on Radon.

PI: MEZQUITA PEREZ, LAURA
Funding: BUNDESAMT FUER STRAHLENSCHUTZ
Beneficiary organization: FRCB-IDIBAPS
Reference: H2020-NFRPCURS_25_01
Amount: 12,000 €
Duration: 01/09/2024 to 31/08/2025

Efecto del Tratamiento agudo con corticoides endovenosos en las partes blandas en fracturas de pilón tibial, retropié y mediopié en relación con tiempo desde ingreso hasta tratamiento quirúrgico

PI: GARCIA ELVIRA, RUBEN
Funding: AO Foundation AO Global Networks
Beneficiary organization: FRCB-IDIBAPS
Reference: 2021-AOTESASPAIN_003
Amount: 7,254.75 €
Duration: 15/01/2022 to 30/09/2025

MOLECULAR MEASURABLE RESIDUAL DISEASE (MRD) MONITORING BY HIGH-THROUGHPUT TECHNIQUES IN PATIENTS TREATED WITH CART19 THERAPY

PI: LOPEZ GUERRA, MONICA
Funding: Thermo fisher scientific inc.
Beneficiary organization: FRCB-IDIBAPS
Reference: THERMOONCOCRG_22_01
Amount: 186,393.29 €
Duration: 28/06/2023 to 30/09/2025

Early detection of perianal fistulizing - Early detection of perianal fistulizing disease- Pathophysiology and Imaging

PI: SALAS MARTINEZ, MARIA AZUCENA
Funding: THE LEONA M & HARRY B HELMSLEY CHARITABLE TRUST
Beneficiary organization: FRCB-IDIBAPS
Reference: 2008-04050
Amount: 1,745,753 €
Duration: 25/11/2019 to 28/11/2025

HUNTER: Hepatocellular Carcinoma Expediter Network

PI: LLOVET BAYER, JOSEP MARIA
Funding: Newcastle University Accounts Payable
Beneficiary organization: FRCB-IDIBAPS
Reference: AA_17_03
Amount: 0.01 €
Duration: 01/11/2018 to 30/11/2025

CRCNS US-Spanish Research Proposal: Circuit mechanisms of priors and learning during decision making

PI: DE LA ROCHA VAZQUEZ, JAIME
Funding: Massachussets Institute of Technology
Beneficiary organization: FRCB-IDIBAPS
Reference: NSF_CRCNS_21_01
Amount: 0.01 €
Duration: 01/12/2022 to 30/11/2025

Psoriasis, a metabolic dysregulation of the innate immune system? Targeting ZEB1 in macrophages as a new therapeutic approach to psoriasis

PI: POSTIGO ANGON, ANTONIO ANDRES
Funding: LEO FOUNDATION
Beneficiary organization: FRCB-IDIBAPS
Reference: LEO_19_01
Amount: 491,478 €
Duration: 01/03/2020 to 31/12/2025

PPMI - Parkinson's Progression Markers Initiative (PPMI) study

PI: ALDECOA ANSORREGUI, IBAN
Funding: Michael J. Fox Foundation for Parkinson
Beneficiary organization: FRCB-IDIBAPS
Reference: MJFF-024484
Amount: 52,683.78 €
Duration: 01/01/2021 to 31/12/2025

Deciphering the molecular signatures of gestational food cravings as drivers of eating disorders in the offspring

PI: HADDAD TOVOLLI, ROBERTA
Funding: Brain and Behaviour Research Foundation
Beneficiary organization: FRCB-IDIBAPS
Reference: BBRF_YI_23
Amount: 64,218 €
Duration: 15/01/2024 to 14/01/2026

Effects of circulating extracellular vesicles on pancreatic islets during obesity

PI: SERVITJA DUQUE, JOAN MARC
Funding: EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES
Beneficiary organization: FRCB-IDIBAPS
Reference: EFSD/BOEHR_22_01
Amount: 100,000 €
Duration: 09/01/2023 to 31/01/2026

A new target for the treatment of acute and chronic itch

PI: Gasull Casanova, Xavier
Funding: LEO FOUNDATION
Beneficiary organization: FRCB-IDIBAPS
Reference: LF-OC-22-001114
Amount: 351,488.65 €
Duration: 01/02/2023 to 31/01/2026

Type 2 inflammation and olfactory loss in chronic rhinosinusitis with nasal polyps: Role of Mepolizumab in olfactory cell neurogenesis

PI: MULLOL MIRET, JOAQUIM
Funding: Glaxosmithkline Research & Development Limited
Beneficiary organization: FRCB-IDIBAPS
Reference: 14859
Amount: 389,318.8 €
Duration: 01/09/2023 to 14/03/2026

Preclinical evaluation of Lilly LRRK2 inhibitors for Parkinson's disease using phosphoproteomic analysis

PI: EZQUERRA TRABALON, MARIO ANTONIO
Funding: LILLY, SAU
Beneficiary organization: FRCB-IDIBAPS
Reference: LILLY_RAP_23_01
Amount: 242,258.79 €
Duration: 19/03/2024 to 18/03/2026

Dissecting the role of the 14q32 region in hepatoblastoma "Hblast14"

PI: SANCHO BRU, PAU
Funding: Worldwide Cancer Research
Beneficiary organization: FRCB-IDIBAPS
Reference: 23-0356
Amount: 245,573.14 €
Duration: 01/04/2023 to 31/03/2026

Dissecting the cellular and molecular atlas of Rheumatoid Arthritis (RA) in sustained remission to identify pathways maintaining Remission and Triggering Flares

PI: CAÑETE CRESPILLO, JUAN DE DIOS
Funding: FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS
Beneficiary organization: FRCB-IDIBAPS
Reference: FOREUM_21_02
Amount: 90,000 €
Duration: 01/04/2023 to 31/03/2026

Cell-Specific Epigenomic Changes in iPSC-Derived Oligodendrocytes from MSA Patients: Effects of α-Synuclein Fibril Exposure in a Disease-Specific Cell Model

PI: COMPTA HIRNYJ, YAROSLAU
Funding: King Baudouin Foundation - EVPA
Beneficiary organization: FRCB-IDIBAPS
Reference: KBF_MSA_24_01
Amount: 9,567.58 €
Duration: 22/05/2025 to 21/05/2026

Decoding tanycytic mitochondrial dynamics in nutrient sensing and metabolic health.

PI: CLARET CARLES, MARC
Funding: EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES
Beneficiary organization: FRCB-IDIBAPS
Reference: EFSD/LILLY_23_01
Amount: 100,000 €
Duration: 01/07/2024 to 30/06/2026

COVID-19 in patients under treatment with anti-CD20 monoclonals: clinical features and outcome

PI: SORIANO VILADOMIU, ALEJANDRO
Funding: GILEAD SCIENCES, INC
Beneficiary organization: FRCB-IDIBAPS
Reference: GILEAD_ESR_24_01
Amount: 158,224 €
Duration: 08/07/2025 to 07/07/2026

Mutimodal single cell profiling of tumor cell and microenvironment interactions driving clinical evolution and therapeutic responses in Mantle Cell Lymphoma

PI: CAMPO GUERRI, ELIAS
Funding: ASTRAZENECA UK LTD.
Beneficiary organization: FRCB-IDIBAPS
Reference: ASTRAZ_HEMAT_22_1
Amount: 647,255.72 €
Duration: 04/08/2022 to 03/08/2026

EHIN - Epithelioid Hemangioendothelioma International Network.

PI: RIMOLA GIBERT, JORDI
Funding: EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Beneficiary organization: FRCB-IDIBAPS
Reference: EASL_RG_21_01
Amount: 50,000 €
Duration: 01/09/2021 to 31/08/2026

RIBOLARIS-PREDICT - Genomic-Based Biomarkers for Predicting Ribociclib Response in Early-Stage Hormone Receptor-Positive and HER2-Negative Breast Cancer (RIBOLARIS-PREDICT)

PI: PRAT APARICIO, ALEIX
Funding: Breast Cancer Research Foundation - BCRF
Beneficiary organization: FRCB-IDIBAPS
Reference: BCRF_AAP_24
Amount: 200,213.66 €
Duration: 01/10/2024 to 30/09/2026

ATLAX - Characterizing the signals from adipo-liver axis in NASH and unveiling their utility as disease biomarkers.

PI: GRAUPERA GARCIA MILA, ISABEL
Funding: Pfizer International LLC
Beneficiary organization: FRCB-IDIBAPS
Reference: PFIZER_NASH_A_22_1
Amount: 127,775.17 €
Duration: 08/11/2023 to 31/12/2026

Single cell subclonal characterization and evolution of the genome and transcriptome in IgM monoclonal gammopathy

PI: MORENO FAJARDO, DAVID FERNANDO
Funding: International Waldenstrom's Macroglobulinemia Foundation
Beneficiary organization: FRCB-IDIBAPS
Reference: IWMF_KCDA_24_01
Amount: 146,603.01 €
Duration: 17/02/2025 to 16/02/2027

Transcriptomic impact of blocking IL-5 with mepolizumab on CD4+T lymphocytes from patients with EGPA. Search for predictors of response

PI: ESPIGOL FRIGOLE, GEORGINA
Funding: Glaxosmithkline Research & Development Limited
Beneficiary organization: FRCB-IDIBAPS
Reference: 219739
Amount: 164,895.2 €
Duration: 08/09/2023 to 26/02/2027

Enabling Artificial Intelligence (AI) for Early Detection of Melanoma in Smartphone Images

PI: MALVEHY GUILERA, JOSE
Funding: SLOAN KETTERING INSTITUTE FOR CANCER RES
Beneficiary organization: FRCB-IDIBAPS
Reference: MRA_TSA_24_01
Amount: 72,285 €
Duration: 01/06/2024 to 31/05/2027

PREDICTION OF TREATMENT NEEDS USING A HYBRID ARTIFICIAL INTELLIGENCE-BASED MANAGEMENT ASSISTANT (ALMA) TOOL IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

PI: ZARRANZ VENTURA, JAVIER
Funding: Foundation of the Society of Retina Specialists
Beneficiary organization: FRCB-IDIBAPS
Reference: EURETINA_24_1
Amount: 227,503 €
Duration: 01/06/2025 to 31/05/2027

MULTIlayer Predictive models for relapsed MCL after ibrutinib as first line therapY (MULTIPLY)

PI: BEA BOBET, SILVIA MARGARITA
Funding: Ludwig-Maximilians-Universitaet Muenchen
Beneficiary organization: FRCB-IDIBAPS
Reference: LLS_MCL_22_2
Amount: 221,720 €
Duration: 01/07/2023 to 30/06/2027

BioRTC Computational Neuroscience Course

PI: COMPTE BRAQUETS, ALBERT
Funding: Simons Foundation
Beneficiary organization: FRCB-IDIBAPS
Reference: 00009921
Amount: 71,009.28 €
Duration: 01/09/2024 to 31/08/2027

RICHARDIII - A pilot study on the use of ARI-0003 cells (dual anti-CD19/CD9 chimeric antigen receptor T-cells) for patients with relapsed/refractory Richter's transformation

PI: DELGADO GONZÁLEZ, JULIO
Funding: Cancer Research Institute
Beneficiary organization: FRCB-IDIBAPS
Reference: INT_CRI_CIG_23_01
Amount: 942,595.99 €
Duration: 01/01/2025 to 31/12/2027

HeBA - Barcelona 2022 PPMI Healthy Brain Aging Initiative

PI: MARTI DOMENECH, MARIA JOSEFA
Funding: Michael J. Fox Foundation for Parkinson
Beneficiary organization: FRCB-IDIBAPS
Reference: MJFF-022187
Amount: 968,050.79 €
Duration: 01/06/2022 to 30/11/2028

CARTALLEU - Phase 2 clinical trial to evaluate the efficacy and safety of varnimcabtagene autoleucel for relapsed/refractory adult acute lymphoblastic leukaemia

PI: DELGADO GONZÁLEZ, JULIO
Funding: FUNDACIÓN CIENTIFICA ASOCIACIÓN ESPAÑOLA CONTRA EL CANCER
Beneficiary organization: FRCB-IDIBAPS
Reference: ATTRACT_23_01
Amount: 0.01 €
Duration: 01/04/2024 to 31/03/2029

PF_MARFANS_Egea - Financiación para un proyecto de investigación liderado por el Dr. Egea

PI: Egea Guri, Gustavo
Funding: MARFANS
Beneficiary organization: FRCB-IDIBAPS
Reference: 12498-25 FRCB
Amount: 400,000 €
Duration: 06/06/2025 to 01/09/2029

MULTICENTER TRIAL OF VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (CART19-BE-02 TRIAL)

PI: LOPEZ GUILLERMO, ARMANDO
Funding: EHA (EUROPEAN HEMATOLOGY ASSOC.)
Beneficiary organization: FRCB-IDIBAPS
Reference: EHA-EBMT_AWARD_01
Amount: 10,000 €
Duration: 01/07/2025 to 30/06/2030

BLOOD a-SYNUCLEIN AGGREGATION ASSAY AS A NOVEL DIAGNOSTIC TOOL FOR PARKINSON’S DISEASE

Beneficiary: DE MENA ALVAREZ, LORENA
Director: FERNANDEZ SANTIAGO, RUBEN
Funding: US Department of Defence
Beneficiary organization: FRCB-IDIBAPS
Reference: DOD_PRP_23_01
Amount: 328,679.43 €
Duration: 01/09/2024 to 31/08/2026

The Edmond J. Safra Fellowship in Movement Disorders - Hospital Clinic Barcelona

Beneficiary: LAZARO HERNANDEZ, CARLOS
Director: VALLDEORIOLA SERRA, FRANCESC
Funding: Michael J. Fox Foundation for Parkinson
Beneficiary organization: FRCB-IDIBAPS
Reference: MJFF-023487
Amount: 170,928 €
Duration: 01/09/2023 to 31/08/2026

RETRACER - RET Expression TRacking to Assess CDK4/6-Inhibitor and Endocrine therapy Resistance emergence

Beneficiary: DI GRAZIA, GIUSEPPE
Director: SCHETTINI, FRANCESCO
Funding: EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)
Beneficiary organization: FRCB-IDIBAPS
Reference: ESMO_2025_01
Amount: 61,000 €
Duration: 01/03/2026 to 28/02/2027

KALYX - (KRAS And Lung cancer: eXposome study) - The exposome study in KRAS-mutant non-small cell cancer patients

Beneficiary: MEAZZA PRINA, MARCO
Director: MEZQUITA PEREZ, LAURA
Funding: EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)
Beneficiary organization: FRCB-IDIBAPS
Reference: ESMO_2025_02
Amount: 61,000 €
Duration: 01/03/2026 to 28/02/2027

The ORCHID study - Overcoming Early Relapse on Adjuvant CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer: Mechanisms of Resistance and Therapeutic Strategies (The ORCHID Study).

Beneficiary: MARTINELLI, GIULIO
Director: BERGAMINO SIRVEN, MILANA ARANTZA A
Funding: EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)
Beneficiary organization: FRCB-IDIBAPS
Reference: ESMO_2025_03
Amount: 61,000 €
Duration: 02/02/2026 to 01/02/2027